Research Article

Luteolin-Rich Extract of *Thespesia garckeana* F. Hoffm. (Snot Apple) Contains Potential Drug-Like Candidates and Modulates Glycemic and Oxidoinflammatory Aberrations in Experimental Animals

Uchenna Blessing Alozieuwa, Bashir Lawal, Saidu Sani, Amos Sunday Onikanni, Obinna Osuji, Yunusa Olatunji Ibrahim, Shukurat Bisola Babalola, Gomaa Mostafa-Hedeab, Abdulrahman A. Alsayegh, Sarah Albogami, Gaber El-Saber Battha, Alexander T. H. Wu, Hsu-Shan Huang, and Carlos Adam Conte-Junior

1Department of Biochemistry, Faculty of Natural and Applied Sciences, Veritas University Abuja, FCT-Abuja, Nigeria
2PhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei and Academia Sinica, Taipei 11031, Taiwan
3Graduate Institute for Cancer Biology & Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan
4Department of Biochemistry and Molecular Biology, Faculty of Science, Federal University Ndufu-Alike Ikwo, P.M., B 1010 Abakaliki, Ebonyi State., Nigeria
5Department of Chemical Sciences, Biochemistry Unit, Afe Babalola University, Ado-Ekiti, Ekiti State, Nigeria
6College of Medicine, Graduate Institute of Biomedical Science, China Medical University, Taiwan
7Department of Chemistry, Faculty of Physical Sciences, Alex-Ekwueme Federal University Ndufu-Alike, Ebonyi State, Nigeria
8Department of Biochemistry, Federal University of Technology, Minna, Nigeria
9Department of Chemistry, Federal University of Technology, Minna, Nigeria
10Pharmacology Department & Health Research Unit, Medical College Jouf University, Jouf, Saudi Arabia
11Pharmacology Department Faculty of Medicine, Beni-Suef University, Egypt
12Clinical Nutrition Department, Applied Medical Sciences College, Jazan University, Jazan 82817, Saudi Arabia
13Department of Biotechnology, College of Science, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia
14Department of Biotechnology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour 22511, AlBeheira, Egypt
15TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei 11031, Taiwan
16The PhD Program of Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan
17Clinical Research Center, Taipei Medical University Hospital, Taipei Medical University, Taipei 11031, Taiwan
18Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 11490, Taiwan
19School of Pharmacy, National Defense Medical Center, Taipei 11490, Taiwan
20PhD Program in Biotechnology Research and Development College of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan
21Center for Food Analysis (NAL), Technological Development Support Laboratory (LADETEC), Federal University of Rio de Janeiro (UFRJ), Cidade Universitária, Rio de Janeiro 21941-598, Brazil

Correspondence should be addressed to Alexander T. H. Wu; chaw1211@tmu.edu.tw and Hsu-Shan Huang; huanghs99@tmu.edu.tw

Received 23 February 2022; Revised 16 June 2022; Accepted 13 July 2022; Published 30 July 2022

Academic Editor: Cassiano Felippe Gonçalves-de-Albuquerque

Copyright © 2022 Uchenna Blessing Alozieuwa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The present study evaluated the polyphenolic contents and hypoglycemic, antioxidant, and anti-inflammatory effects of the diethyl ether fraction of *Thespesia garckeana* using various *in vitro* and *in vivo* models. Total phenol and flavonoid contents of the extract were 613.65 ± 2.38 and 152.83 ± 1.56 mg/100 g dry weight, respectively. The extract exhibited *in vitro* antioxidant activities against DPPH, FRAP, LPO, and ABTS with respective half-maximal inhibitory concentration (IC50) values of 30.91 ± 0.23, 16.81 ± 0.51, 41.29 ± 1.82, and 42.39 ± 2.24 μg/mL. *In vitro* anti-inflammatory studies using membrane stabilization, protein denaturation, and proteinase activities revealed the effectiveness of the extract with respective IC50 values of 54.45 ± 2.89, 93.62 ± 3.04, and 56.60 ± 2.34 μg/mL, while *in vitro* hypoglycemic analysis of the extract revealed inhibition of α-amylase (IC50 64.59 ± 3.29 μg/mL) and enhancement of glucose uptake by yeast cells. Interestingly, the extract demonstrated *in vivo* hypoglycemic and anti-inflammatory effects in streptozotocin- (STZ-) induced diabetic and xylene-induced ear swelling models, respectively. In addition, the extract improved insulin secretion, attenuated pancreatic tissue distortion and oxidative stress, and increased the activities of superoxide dismutase (SOD), catalase, and reduced glutathione (GSH), while reducing the concentration of LPO in the diabetic rats. A high-performance liquid chromatography (HPLC) analysis identified the presence of catechin (6.81e – 1 ppm), rutin (8.46e – 1 ppm), myricetin, apigenin (4.019e – 1 ppm), and luteolin (15.09 ppm) with respective retention times (RTs) of 13.64, 24.269, 27.781, 29.58, and 32.23 min, and these were subjected to a pharmacoinformatics analysis, which revealed their drug-likeness and good pharmacokinetic properties. A docking analysis hinted at the potential of luteolin, the most abundant compound in the extract, for targeting glucose-metabolizing enzymes. Thus, the present study provides preclinical insights into the bioactive constituents of *T. garckeana*, its antioxidant and anti-inflammatory effects, and its potential for the treatment of diabetes.

1. Introduction

Diabetes mellitus (DM) is a category of metabolic disorders that affect glucose, lipid, and protein metabolism and consequently affect the overall health status [1, 2]. The prevalence of diabetes is very high, affecting millions of people globally [3]. It is characterized by the development of insulin resistance, abnormal insulin signaling, oxidative stress [4], inflammation [5], and organ dysfunction [6], leading to decreased life quality and high mortality [7]. In the past few decades, DM, particularly type 2 DM (T2DM), has become a global health problem that threatens millions of people in both developed and developing countries [2]. According to the Diabetes Atlas (10th edition) of the International Diabetes Federation (IDF) [8], there are 357 million people living with diabetes in 2021, and about 783 million cases are expected by 2045 [8], compared to 151 million sufferers in 2000 [9–11].

Although the pathogenesis and pathophysiology of T2DM are extremely complex and not fully understood, accumulating evidence has revealed that free radical generation, oxidative stress, and inflammation play critical implicative roles in the development of T2DM [12, 13]. Inflammation, a complex physiological response to injury and infection, plays a pivotal role in the development of chronic disorders, including arthritis, asthma, atherosclerosis, and cancers [14]. Experimental and clinical studies have provided evidence of the important roles of inflammation in DM [15, 16]. Reactive nitrogen species (RNS) and reactive oxygen species (ROS) were clearly implicated in the pathology of various diseases including aging, cancers, cardiovascular diseases (CVD), neuronal impairment, and diabetic complications [14, 17]. During hyperglycemia, the generation of free radicals (RNS and ROS), autooxidation of glucose, and depletion of endogenous antioxidants lead to oxidative stress and inflammatory conditions, apoptosis of pancreatic islet β cells, and impaired insulin secretion [18]. In addition, inflammation and oxidative stress also contribute to the development of diabetic complications such as hypertension, retinopathies, nephropathies, and neuropathies [19, 20].

Over the years, synthetic and chemical antioxidants and antidiabetic medications have been developed for treating diabetes and its associated complications [21]. However, their clinical applications have been limited by the loss of efficacy and more importantly by associated side effects including diarrhea, lactic acidosis, flatulence, and acute hepatitis [22, 23]. Hence, there is a need to focus on seeking new alternatives. Moreover, evidence from traditional health practice and experimental studies suggested that natural products, particularly medicinal plants, are rich sources of therapeutic agents that can offer better efficacy with minimal side effects compared to conventional therapies [24–26]. Thus, exploring bioactive metabolites from medicinal plants may offer multiflank and acquire control while modulating oxidative inflammatory aberrations and improving prognoses of diabetes and its complications. *Thespesia garckeana* F. Hoffm., known as ‘snout apple’ or ‘kola of Tula,’ is a reputable medicinal plant that is widely distributed in Africa and some other tropical countries [27, 28]. As a traditional medicine, the plant is widely used for treating rheumatism, infections, diabetes, liver diseases, reproductive impairment, and other diseases [28, 29]. Several biological activities of the plant were also reported in the literature [28, 30–32]. Herein, we evaluated the hypoglycemic, antioxidant, and anti-inflammatory effects of the diethyl ether fraction of *T. garckeana* using various *in vitro* and *in vivo* models. Further characterization of the extract revealed the presence of various compounds which were subjected to a pharmacoinformatics analysis, thus unveiling their drug-likeness, good pharmacokinetics (PKs), and potential hypoglycemic properties. Altogether, our study established the preclinical efficacy of *T. garckeana* extract against inflammation, glycemic impairment, and oxidative stress, suggesting its future use for developing alternative therapies against diabetes complications.

2. Materials and Methods

2.1. Plant Collection, Extraction, and Fractionation. *Thespesia garckeana* plant was obtained from the Gombe State,
Tula Village, Kaltungo Local Government Area (Latitude 9°48′51″N and Longitude 11°18′32″E) Nigeria. Plant authentication was conducted at the Ebonyi State University, Nigeria, and a specimen voucher identification number was reported. The pulp was air-dried to a constant dry weight at 25°C for 2 weeks before being subjected to pulverization with the aid of a mechanical blending machine. Three hundred grams (300 g) of the pulverized sample was subjected to cold maceration in 1.5 L of methanol for 72 h. The resulting crude extract after concentration was further subjected to fractionation with diethyl ether, ethyl acetate, and n-butanol successively and the resulting fractions; diethyl ether (7.9% yield), ethyl acetate (3.10% yield), and n-butanol (2.45% yield) fractions were concentrated in a rotary vacuum evaporator under reduced pressure. The resulting diethyl ether fraction (diethyl-eth_T. garckeana) which demonstrated the highest yield and phytochemical compositions in preliminary screening was used for subsequent analysis.

2.2. Analysis of Total Phenol and Flavonoid Contents. The total flavonoid content of the diethyl-eth fraction of T. garckeana was determined according to the method of Chang et al. [33], while the total phenol content was evaluated using the Folin-Ciocalteau’s reagent as described by Singleton et al. [34]. Gallic acid (total phenols) and quercetin (total flavonoids) were used to prepare the calibration curves.

2.3. In Vitro Antioxidant Assays. The in vitro antioxidant effects of diethyl-eth_T. garckeana were evaluated using the DPPH, FRAP, ABTS, and LPO assays. The DPPH assay was conducted based on the scavenging ability of the extract on DPPH radicals [35]. FRAP activity was assayed according to the method of Oyaizu [35]. The extract was incubated in K3[Fe(CN)6] supplemented phosphate buffer at 50°C for 20 min, after which 10% TCA was added. The resulting solution was centrifuged and color development in the presence of 0.1% ferric chloride was monitored at 700 nm. The thiobarbituric acid-reactive substance (TBARS) protocol described by Panjamurthy et al. [36] was employed for the LPO analysis, while the ABTS assay was done as reported by Re et al. [37].

2.4. In Vitro Hypoglycemic Assays. Standard analysis protocol for alpha-amylase inhibition described by Worthington [38] was employed for the in vitro hypoglycemic analysis of the extract. Briefly, the extract/acarbose (12.5 ~ 100 μg/ml) mixed in an enzymatic porcine pancreatic solution was incubated with a starch solution for 30 min at 37°C, followed by the addition of 10 μL of HCl (1 M) and iodine reagent for color development. In the analysis of glucose uptake by yeast cells, glucose solution (5 ~ 25 mM) was incubated (37°C for 10 min) with the extract. A yeast suspension was added to the reaction mixture and incubated for another 45-60 min, after which glucose concentration was estimated.

2.5. In Vitro Anti-Inflammatory Assays. The in vitro anti-inflammatory activities of the diethyl-eth_T. garckeana were evaluated by using the human red blood cell (RBC and HRBC) membrane stabilization, inhibition of protein denaturation, and proteinase inhibitory assays. The protein denaturation inhibition was assayed as described of Mizushima and Kobayashi [39], while the method of Oyedepo and Femurewa [40] was used for the proteinase inhibition assay. In the HRBC assay, a 10% human RBC suspension was incubated with the extract solution at 50-55°C for 30 min [41]. The resulting solution was centrifuged at 2500 rpm for 5 min, and the reaction changes was monitored at 560 nm.

2.6. Analysis of Toxicity and Extract Tolerated Dose. The diethyl-eth_T. garckeana was subjected to an acute toxicity study to evaluate its safety and maximum tolerated dose upon oral administration according to the protocol described by Lorke [42]. Briefly, a total of eighteen (18) rats were grouped into six (6) and administered with 10, 100, 1000, 1600, 2800, and 5000 mg/kg bw of diethyl-eth_T. garckeana to groups I-VI, respectively. The extract was administered once orally, after which the rats were observed for any sign of adverse toxicity and mortality within 14 days’ period.

2.7. Oral Glucose Tolerance Test (OGTT). The OGTT was conducted according to the method described by Sisay et al. [43]. A total of twelve (12) overnight starved rats were grouped into 5 (3 rats per group) and treated with 2.0 mL/kg normal saline, 5 mg/kg glibenclamide, 150 mg/kg, and 300 mg/kg dietl-eth_T. garckeana for groups I-IV, respectively. After 30 minutes of treatment, 2 g/kg bw of glucose was orally administered to rats in each group. The blood glucose level was determined at 0 minutes (basal blood glucose level) and at intervals of 30 for a period of 2 hrs.

2.8. Analysis of In Vivo Antidiabetic Activities in Rats. The diethyl-eth_T. garckeana was evaluated for the in vivo antidiabetic effects in albino rats. Experimental rats were acquired from the experimental rodent facility of AE-FUNAI, Nigeria. Animal experiments were consented by the ethical committee of the AE-FUNAI, Nigeria. Streptozotocin (STZ; 40 mg/kg) was intraperitoneally administered to overnight starved rats, and rats with FBS > 200 mg/kg were considered diabetic [44]. Rats were rationed into 4 groups and treated with the dietl-eth_T. garckeana at 150 (group 1) and 300 mg/kg (group 2), 2 mL/kg normal saline (group 3), and 200 mg/kg metformin (group 4). Healthy rats were assigned to the fifth group to serve as the control. Treatments were given on a daily basis for a period of 21 days via oral route. The fasting blood sugar concentration and animals’ body weight were checked during the study period.

2.9. In Vivo Anti-Inflammatory Analysis (Xylene-Induced Ear Swelling Assay). The dietl-eth_T. garckeana was evaluated for its in vivo anti-inflammatory effects in mice using a xylene-induced ear edema test [45, 46]. Healthy mice were divided into five (n = 5) groups and administered orally with saline, dietl-eth_T. garckeana (150 and 300 mg/kg BW), or 200 mg/kg aspirin for 7 days. On the eighth day, the posterior and anterior surfaces of the rat’s right ear were scrubbed with 0.02 mL aliquot of xylene. Measurement of the ear thickness was done, and the ear inflammation volume was
computed as the weight differences between the right and the left ears. Orbital blood sample was also collected and analyzed for the levels of white blood cell counts.

2.10. Collection and Processing of Samples. Experimental rats were euthanized under diethyl ether vapor for few minutes, and blood were obtained through cardiac puncture. The coagulated blood was centrifuged for 15 min (3000 × g) and the separated serum were stored at 4°C [47, 48]. The rat’s pancreases and liver tissues were harvested, homogenized in phosphate buffer (0.1 M, pH 7.4, 1:10 w/v) and centrifuged at 10,000 × g for 10 min at 4°C.

2.11. Tissue Assays for Antioxidant Parameters. The in vivo antioxidant effects of the extract were evaluated in liver homogenate using the lipid peroxidation (LPO), superoxide dismutase (SOD), reduced glutathione (GSH), and catalase (CAT) assays. The LPO assay was conducted by measuring the tissue levels of TBA Rs [49], while the modified colorimetric method of Kum-Tatt and Tan [50] was adopted for GSH assay. The activity of SOD was evaluated by using an established protocol [51]. The tissue homogenate was incubated with carbonate buffer (pH 10.2) in the presence of 0.3 mM adrenaline. The increase in absorbance at an interval of 30 s were monitored at 480 nm [51]. CAT activity was determined using a standard protocol [52]. The liver homogenate (0.1 mL) in phosphate buffer (0.01 M, pH 7.0) was incubated with 2 M hydrogen peroxide (H2O2) for 20 min. This was followed by the addition of a dichromate acetate reagent to terminate the reaction. The changes in absorbance were monitored at the wavelength of 620 nm and the activity of CAT was expressed as a unit of H2O2/ mg protein [52].

2.12. Measurement of Insulin Levels. The Insulin ELISA kit (Calbiochem-Behring Corp, CA; catalog no. IN374S) was used for the analysis of pancreatic and serum insulin concentrations as per the manual instructions.

2.13. High-Performance Liquid Chromatography (HPLC). The dietl-eth. T. garckeana was subjected to HPLC analysis according to the method described in our previous study [20]. A hundred milligram (100 mg) of dietl-eth. T. garckeana was dissolved in five millilitres (5 mL) of an HPLC grade methanol. The extract solution was filtered and run on the HPLC (Agilent Technologies 1200) with the following chromatographic conditions: stationary phase (Hypersil BDS C18), mobile phase (acetonitrile and 0.1% formic acid), column dimension of 250 mm × 4.0 mm, injection volume of 10 μL, a flow rate of 0.6 mL/min, detector wavelength of 280 nm, and at gradient mode of elution.

2.14. Pharmacoinformatics Analysis

2.14.1. Analysis of Drug-Likeness and ADMET-PK Properties. The most abundant compounds identified from the dietl-eth. T. garckeana were subjected to analysis of physicochemical properties, drug-likeness, PKs (ADMET), and medicinal chemistry using the ADMET-Lab, ADMET-Sar, and Swiss-ADME servers [53]. The human-intestinal absorption and permeability by blood-brain barrier (BBB) were modeled through the BOILED-EGG and support vector machine (SVM) tools [53].

2.14.2. Analysis of Ligand Receptor Interactions Using Molecular Docking. The most abundant bioactive compounds characterized from the extract was subjected to an analysis of ligand-receptor interactions using molecular docking. The crystal three-dimensional (3D) forms of the compounds were built by the Avogadro visualization tool (version 1.XX) [54], while the PDB files of the target receptors including alpha-amylase and alpha-glucosidase were downloaded from the Protein Data Bank. The mol2 files were transformed into PDB files using PyMOL software, while the PDB formats were transformed to PDBQT using AutoDock Vina [55]. Water molecules were detached, while hydrogen atoms in polar forms and Kollman charges were added to the compounds during predocking preparations [56, 57]. The version 8 of AutoDock Vina tool was used for the receptor-ligand docking as described in previous studies [56, 58, 59], while visualization was conducted using the PyMOL and Discovery studio tools [60].

2.15. Data Analysis. The GraphPad vers. 8.0 software was used for the statistical analysis of replicate data. The one-way type analysis of variance and Student’s t-test were explored for statistical comparison between groups. Data are presented as the mean ± standard error of the mean (SEM), and statistical annotation of “*,” “**,” “***,” or “****” were used to represent the statistical differences corresponding to “p < 0.05,” “p < 0.001,” and “p < 0.001,” respectively.

3. Results and Discussion

3.1. Thespesia garckeana Fraction Exhibited Dose-Related In Vitro Antioxidant Activities. Plants, particularly those that are rich source of flavonoid and polyphenolic compounds, have been effective against various diseases including cancers and diabetes [61]. These phytochemicals are known to exhibit several biological activities including antioxidants, antimicrobial, anticancer, anti-inflammatory, and antidiabetic, etc. [62]. Interestingly, our results demonstrated that dietl-eth. T. garckeana contains total phenol contents of 613.65 ± 2.38 mg/100 g dry weight and total flavonoid contents of 152.83 ± 1.56 mg/100 g dry weight. The flavonoid and phenol contents reported in this study are higher than the total phenol (34.32 and 25.34 mg/100 g) and flavonoid (13.45 and 7.65 mg/100 g) contents previously reported for crude methanol and ethyl-acetate extracts of T. garckeana [28]. The presence of significant-high amounts of phenol and flavonoid contents in the dietl-eth. T. garckeana suggested the ability of the extract to scavenge free radicals, prevent oxidative stress and manage diabetes [62].

The formation of free radicals and oxidative stress play important roles implicated in the development of T2DM [12, 13]. Therefore, the role of antioxidants in preventing the formation of free radicals is crucial to the control of DM [61]. Our in vitro studies revealed significant and dose-related antioxidant activities of the dietl-eth. T.
garckeana in four different in vitro models of antioxidant assays; DPPH, FRAP, LPO, and ABTS, with IC50 values of 30.91 ± 0.23 (Figure 1(a)), 16.81 ± 0.51 (Figure 1(b)), 41.29 ± 1.82 (Figure 1(c)), and 42.39 ± 2.24 μg/mL (Figure 1(d)), respectively. Through the analysis of TBARS levels, we uncovered that the malonaldehyde (MDA) formation has been significantly compromised by dietl-eth_T. garckeana. In addition, the hydrogen donating properties of the extract as a means of radical scavenging has been demonstrated by the DPPH assay [63]. The reduction of Fe3+/Fe2+ as suggested by the FRAP assay also confirmed the scavenging ability of dietl-eth_T. garckeana, thereby transforming reactive radical element into a more stable product. Phenols and flavonoids were implicated in the free radical scavenging abilities and defensive properties of plants against various illnesses [64]. Consequently, the high flavonoid and phenolic contents of dietl-eth_T. garckeana may be appraised for the antioxidants activity of the extract.

3.2. Thespesia garckeana Fraction Exhibited Dose-Related In Vitro Anti-Inflammatory Activities. Inflammation, a complex physiological response to injury and infection, plays a pivotal role in the development of chronic disorders, including arthritis, asthma, atherosclerosis, cancer, and DM [14]. Interestingly, T. garckeana exhibited dose-related anti-inflammatory activities. Our in vitro anti-inflammatory studies using membrane stabilization, protein denaturation, and proteinase activities revealed the effectiveness of the extract with respective IC50 values of 54.45 ± 2.89, 93.62 ± 3.04, and 56.60 ± 2.34 μg/mL (Figures 2(a)–2(c)). The erythrocytic membrane exhibits some similarities with the lysosomal membrane and its stabilization implies that the dietl-eth_T. garckeana may well stabilize lysosomal membranes [65]. This is important for restraining the inflammatory response by halting the lysosomal releases of active neutrophils, such as proteases and bacterial enzymes, which may induce tissue inflammation and injury upon extracellular release [66]. The dietl-eth_T. garckeana promoting
membrane stabilization also suggests its potential for mitigating phospholipases release thereby preventing the generation and activities of inflammatory mediators [67]. Proteinase inhibitory activity was studied to further explain the anti-inflammatory mechanism of dietl-eth_T. garckeana. Neutrophils contain high levels of serine proteinase [65] that play a vital tissue damaging role during inflammatory events [68] and inhibitors of this proteinase protect against the damage [69]. Interestingly, the dietl-eth_T. garckeana exhibited dose related antiproteinase activity with IC\textsubscript{50} of 56.60 ± 2.34 μg/mL. These results provide evidence for proteinase inhibition as an additional mechanism of the anti-inflammatory effect of dietl-eth_T. garckeana. Altogether, these data suggest that T. garckeana extract would be useful for averting inflammatory complications that could be associated with diabetes.

3.3. Thespesia garckeana Fraction Demonstrated Safety Profile in Acute Oral Toxicity Study. According to the data obtained from this study, dietl-eth_T. garckeana demonstrated a good safety profile with a 50%lethal dose (LD\textsubscript{50}) > 500 mg/kg bw and a safe dose of 1000 mg/kg bw (Table 1). No animal mortality was observed during the study. In addition, rats dosed with 10, 1000, and 1000 mg/kg bw were bereft of adverse health or physiological changes, suggesting the safety of the extract at doses ≤ 100 mg/kg bw. Conversely, rats treated with 1600, 2800, and 5000 mg/kg exhibited varying levels of adverse effects ranging from restlessness, hyperactivity, redness of the eyes, and profuse breathing. According to Hodge and Sterner [70], substances that demonstrate an LD\textsubscript{50} of 5000 mg/kg in rats should be considered harmless substances. This result is in agreement with the findings of Iyojo et al. [71], who reported no mortality in rabbits administered different extracts of T. garckeana pulp at 5000 mg/kg. Altogether, dietl-eth_T. garckeana demonstrated high LD\textsubscript{50} and is safe for use as an oral remedy at doses ≤ 100 mg/kg bw. Thus, the high safety of this plant upon oral exposure justifies the widespread use of this plant for treating various ailments by traditional healers in northern Nigeria.

3.4. Thespesia garckeana Fraction Exhibited Dose-Related In Vitro Hypoglycemic Activities. The inhibition of carbohydrate-metabolizing enzymes and regulation of blood glucose levels are very critical to the management of DM [72]. The dietl-eth_T. garckeana also demonstrated a
hypoglycemic effect via inhibition of α-amylase (IC₅₀: 64.59 ± 3.29 µg/mL) and enhanced glucose (5, 10, and 25 mM) uptake by yeast cells in a dose-related manner (Figure 3).

Inhibitors of α-amylase, a starch-catabolizing enzyme, are widely used as oral hypoglycemic agents for the regulation of sugar levels of T2DM patient [73]. However, most of these inhibitors are synthetic with off-limit activity and associated side effects [74]. Consequently, the current results verify that the dietl-eth_ T. garckeana exerts its hypoglycemic via the inhibition of carbohydrate-catabolizing enzymes, including the α-amylase. The inhibitory activities of the dietl-eth_T. garckeana on α-amylase activities suggest the attenuation of postprandial blood glucose increase by decreasing the carbohydrates flow into the bloodstream after carbohydrate intake [75].

Glucose is preferred by yeast as a primary source of fuel, and glucose absorption by yeast cells is simulate that occurring in the mammalian intestinal lumen; thus, yeast has become a commonly used model to study glucose absorption [76]. According to the present study, dietl-eth_T. garckeana significantly enhanced glucose uptake by yeast cells in a dose-related manner. This is important for the efficient utilization and control of glucose levels. Interestingly, a linear relationship between glucose concentration and rates of glucose uptake by the yeast cells was observed. This is in line with the finding of Keshala et al. [61] who reported a concentration-dependent increase in glucose uptake by yeast cells in the presence of plant extract. Collectively, the dietl-eth_T. garckeana exhibited dose-related in vitro hypoglycemic activities and, thus, could be regarded as a natural product with potential for the management of DM.

3.5. The dietl-eth_T. garckeana demonstrated hypoglycemic effect in Oral glucose tolerance test. In the present study, the evaluation of dietl-eth_T. garckeana for possible antidiabetic effect was also conducted using the oral glucose tolerance test. There were initial increases in glucose levels at 30 minutes of glucose dosing after which progressive decreases were observed from 30 minutes to 2 hours in all the treatment as well as the control rats. However, significant ($p < 0.05$) decreases in the glucose levels of rats treated with the 300 mg/kg dietl-eth_T. garckeana, as well as the standard control group, were observed when compared with the non-treated glucose-loaded rats (Figure 4). Our result has shown that the extract can decrease postprandial blood glucose levels and improve peripheral glucose uptake and utilization in rats. The OGTT corroborate the effects of the plant extracts on insulin release by the B cells of the islets of Langerhans in diabetic rats. Postprandial elevated sugar level is with an increased risk of diabetes-associated secondary complications [77]. Therefore, the OGTT suggested the potential usefulness of dietl-eth_T. garckeana in T2DM subjects with insulin resistance prone to elevated postprandial sugar level [78].

3.6. The dietl-eth_T. garckeana Demonstrated Hypoglycemic Effect and Improved Insulin Secretion in STZ-Induced Diabetic Rats. Previous experimental studies have proved the therapeutic efficacy of medicinal plants in animal models of diabetes, inflammation, and oxidative stress-associated diseases [79–81]. The in vivo antidiabetic effects of the dietl-eth_T. garckeana was evaluated in STZ-induced diabetic rats. Interestingly, our in vitro findings corroborated with the data generated in vivo. We found that treatment of the STZ-induced diabetic rats with dietl-eth_T. garckeana caused significant and progressive decreases in the fasting blood sugar (FBS) levels in a dose-related manner (Figure 5(a), Table 2) and prevented the body weight loss (Figure 5(b), Table 3), while diabetic untreated rats exhibited progressive increases in FBS levels and body weight loss. At the end of the treatment duration, the extract at 150 and 300 mg/kg demonstrated 62.67% and 78.88% hypoglycemic effects, respectively, while metformin demonstrated higher hypoglycemic activity of 84.25%. Thus, the gradual decreases in FBS and improvement of body weight recorded in the T. garckeana-receiving animal when compared with the untreated diabetic rats presaged the ameliorative effects of the fraction on experimentally induced diabetes.

Under a physiological condition, the pancreatic cells regulate blood glucose levels by regulating β cells of Islets of Langerhans’s activity through insulin secretions. Therefore, the hyperglycemia induced by STZ may be attributed to the impairment of insulin release as a consequence of the destroyed β cells of Islets of Langerhans in the pancreas.
Indeed, we found that the STZ-induced diabetic non-treated rats exhibited significant ($p < 0.05$) decreases in the pancreatic and serum (Figure 5(c)) insulin levels as well as histological distortion of the pancreas (Figure 5(d)) when compared with the control rats, while administrations of the dietl-eth$_T. garckeana$ significantly ($p < 0.01$) increased the serum and pancreatic insulin levels of the 300 mg/kg-treated diabetic rats only. The serum insulin level in 150 mg/kg-treated rats was not significantly ($p > 0.05$) different from diabetic nontreated rats. Furthermore, the pancreatic section of the STZ-induced diabetic nontreated rats shows a pancreatic architecture with loose connective tissue. The parenchymatous portion of acini and islet are distorted and most enriched by adipose tissue (Figure 5(d)). However, in a similar architecture to the normal control rats, the pancreatic section of rats treated with metformin, and the 300 mg/kg extract receiving rats show the well-preserved pancreatic architectures, comprising lobules of exocrine acini separated by thin fibrous septa. Normal islets of Langerhans are seen, and there were no features of significant inflammation or damage seen. These ameliorative effects

![Figure 3: Diethyl-ether fraction of Thespesia garckeana (dietl-eth$_T. garckeana$) demonstrated in vitro dose-related hypoglycemic activities. Bar graphs showing extract dose vs. inhibitory effects of the dietl-eth$_T. garckeana$ on (a) α-amylase inhibition, and yeast glucose uptake inhibition at (b) 5, (c) 10, and (d) 25 mM concentrations of glucose. Values are the mean ± SEM ($n = 3$). IC$_{50}$: half-maximal inhibitory concentration.](image-url)

![Figure 4: Effect of the diethyl-ether fraction of Thespesia garckeana (dietl-eth$_T. garckeana$) on blood glucose levels in oral glucose tolerance test (OGTT). Values are the mean ± SEM. *$p < 0.05$, **$p < 0.01$.](image-url)
of the extract on pancreatic architecture, activity, and insulin secretion might have promoted the effective glucose uptake and utilization [83] and thus restored the glycemic status of the rats. Altogether, this study provides preclinical evidence supporting the potential therapeutic benefits of dietl-eth_T. garckeana in stimulating insulin secretion in STZ-induced diabetic rats.

Figure 5: Diethyl-ether fraction of *Thespesia garckeana* (dietl-eth_T. garckeana) demonstrated a hypoglycemic effect and improved insulin secretion in STZ-induced diabetic rats. Bar graph showing the effects of the dietl-eth_T. garckeana on (a) fasting blood glucose, (b) body weight, and (c) pancreatic and insulin levels in diabetic rats. (d) Cross-section of the STZ-induced diabetic rat's pancreas administered dietl-eth_T. garckeana. Long arrow: islet of Langerhans; short arrow: interlobular septum; red arrow: pancreatic duct; green arrow: acini. Values are the mean ± SEM. "*"p < 0.05," **"p < 0.01," ***"p < 0.001," and ****"p < 0.0001".
secretion and attenuating hyperglycemia in streptozocin-induced diabetic rats.

3.7. The *dietl-eth_T.* *garckeana* Exhibited Antioxidant Activities in Rats with STZ-Induced Diabetes. Inflammation and oxidative stress contribute to the development of diabetic complications such as hypertension, retinopathies, nephropathies, and neuropathies [19, 20]. The generation levels of ROS are controlled by the levels endogenous antioxidant including CAT, GSH, and SOD [84, 85]. In the present study, analysis of liver biochemical parameters of oxidative stress in rats with STZ-induced diabetes revealed significant decreases in the liver activities of antioxidant enzymes including SOD (*p* < 0.01; Figure 6(a)), CAT (*p* < 0.05; Figure 6(b)), and GSH (*p* < 0.01; Figure 6(c)) and increased MDA levels (*p* < 0.001; Figure 6(d)) in STZ-induced diabetic rats compared to the respective normal controls.

The liver is a central detoxification organ of the body and plays a vital role in regulating glucose homeostasis [86]. As a group of insulin-sensitive tissues, the liver is among the primary organs highly susceptible to the effects of hyperglycemia-provoked oxidative stress, which may impair liver integrity [87]. Hyperglycemia, mainly caused by insulin resistance, induces the generation of free radicals by the activated Kupffer cells (phagocytic hepatic macrophages) that help in maintaining the integrity of liver cells [88]. However, these cells are highly susceptible to the effects of the free radicals generated by their own

---

**Table 2: Effect of diethyl-ether fraction of *Thespesia garckeana* on blood glucose levels in STZ-induced diabetic rats.**

| Groups          | 0            | 3            | 7            | 14           | 21           | Glucose reduction (%) |
|-----------------|--------------|--------------|--------------|--------------|--------------|-----------------------|
| Normal          | 89.66 ± 1.76 | 88.06 ± 3.60 | 87.06 ± 4.58 | 90.66 ± 3.71 | 85.05 ± 1.15 | —                     |
| Untreated       | 84.05 ± 3.00 | 442.50 ± 17.50 | 415.5 ± 5.500 | 441.50 ± 18.50 | 518.50 ± 12.50 | —                     |
| 150 mg/kg Dietl_T.G | 82.03 ± 3.01 | 474.50 ± 6.50 | 319.50 ± 14.50 | 258.50 ± 54.5 | 193.55 ± 19.05 | 62.67                 |
| 300 mg/kg Dietl_T.G | 87.00 ± 3.00 | 419.50 ± 2.50 | 269.60 ± 4.40 | 125.70 ± 4.30 | 109.46 ± 5.87 | 78.88                 |
| Metformin       | 86.00 ± 2.08 | 433.33 ± 24.03 | 210.66 ± 15.76 | 169.33 ± 35.25 | 81.66 ± 4.25 | 84.25                 |

Dietl_T.G: diethyl-ether fraction of *Thespesia garckeana*.

**Table 3: Effect of diethyl-ether fraction of *Thespesia garckeana* on body weight gain in STZ-induced diabetic rats.**

| Groups          | 0            | 3            | 7            | 14           | 21           | Weight gain (%)       |
|-----------------|--------------|--------------|--------------|--------------|--------------|-----------------------|
| Normal          | 157.05 ± 2.00 | 159.01 ± 1.54 | 165.22 ± 1.31 | 169.80 ± 1.29 | 176.53 ± 2.64 | 11.05 ± 0.19          |
| Untreated       | 146.85 ± 3.86 | 146.03 ± 9.38 | 138.83 ± 8.60 | 136.17 ± 4.05 | 126.79 ± 3.30 | −15.82 ± 0.03         |
| 150 mg/kg Dietl_T.G | 163.26 ± 9.92 | 160.26 ± 8.93 | 169.25 ± 10.64 | 169.60 ± 8.61 | 169.33 ± 5.30 | 4.01 ± 2.85           |
| 300 mg/kg Dietl_T.G | 158.27 ± 0.72 | 156.42 ± 1.34 | 160.63 ± 0.51 | 161.54 ± 0.68 | 162.19 ± 1.08 | 2.40 ± 1.09           |
| Metformin       | 160.20 ± 0.88 | 154.37 ± 2.84 | 158.42 ± 4.19 | 163.93 ± 3.81 | 169.60 ± 1.49 | 5.53 ± 0.31           |

Dietl_T.G: diethyl-ether fraction of *Thespesia garckeana*.
Table 4: *In vitro* anti-inflammatory effects of the diethyl-ether fraction of *Thespesia* (dietl-eth, *T.* garckeana).

| Treatment                  | Dose (mg/kg BW) | Swelling rate | WBCs (×10^9) |
|----------------------------|-----------------|---------------|---------------|
| dietl-eth, *T.* garckeana  | 150             | 16.71 ± 1.19*** | 106.00 ± 1.73*** |
| dietl-eth, *T.* garckeana  | 300             | 10.41 ± 1.56*** | 98.00 ± 1.1561*** |
| Aspirin                    | 200             | 13.67 ± 1.20*** | 101.00 ± 3.46*** |
| Untreated control          | 2.5 mL/normal saline | 77.33 ± 1.76 | 178.3.46 ± 3.46 |
| Normal control             | Normal control  | —             | 106.00 ± 2.31*** |

Values are the mean ± SD (n = 3). BW: body weight; WBCs: white blood cells; *** p < 0.001.

Figure 7: High-performance liquid chromatography (HPLC) chromatogram and chemical structures of bioactive compounds identified from the diethyl-ether fraction of *Thespesia garckeana*.

Figure 8: Drug-likeness and permeability simulation of compounds identified from the dietl-eth, *T.* garckeana (a) absorption and permeability and (b) drug-likeness modeling of compounds from the diethyl-ether fraction of *Thespesia garckeana*.
| Property                          | Rutin       | Myricetin   | Apigenin   | Luteolin   | Catechin   |
|----------------------------------|-------------|-------------|------------|------------|------------|
| Molecular weight                 | 610.521     | 318.237     | 270.24     | 286.239    | 290.271    |
| Logp                            | -1.687      | 1.694       | 2.57       | 2.282      | 1.546      |
| HB acceptor                     | 16          | 8           | 5          | 6          | 6          |
| HB donor                        | 10          | 6           | 3          | 4          | 5          |
| Physicochemical                  |             |             |            |            |            |
| TPSA                            | 269.43      | 151.59      | 90.9       | 111.13     | 110.38     |
| LogS (solubility)               | 315.283 µg/mL | 191.757 µg/mL | 68.667 µg/mL | 90.101 µg/mL | 273.4303 µg/mL |
| LogD7.4                         | 0.992       | -0.068      | 0.487      | 0.302      | 0.115      |
| Logp                            | -1.687      | 1.694       | 2.577      | 2.282      | 1.546      |
| Papp (cancer cell permeability)  | -6.606 cm/s | -6.63 cm/s  | -4.985 cm/s | -5.123 cm/s | -4.637 cm/s |
| P-glycoprotein-inhibitor        | -0.365      | -0.208      | -0.328     | -0.366     | -0.223     |
| Intestinal absorption (HIA)     | -0.21       | +0.438      | +0.531     | -0.438     | -0.401     |
| Bioavailability                 | +0.572      | +0.557      | +0.542     | +0.557     | -0.487     |
| Plasma protein binding (PPB)    | 76.65%      | 76.595%     | 90.031%    | 91.796%    | 93.86%     |
| Distribution                    |             |             |            |            |            |
| VD (L/kg)                       | -1.052      | -1.391      | -0.578     | -0.934     | -0.67      |
| Blood brain barrier             | -0.018      | -0.369      | -0.464     | -0.464     | +++(0.708) |
| CYP-1A2 inhibitor               | -0.197      | +++(0.968)  | +++(0.987) | +++(0.968) | -0.034     |
| CYP-1A2 subst.                  | -0.258      | -0.376      | -0.408     | -0.412     | -0.368     |
| CYP-3A4 inhibitor               | +0.518      | -0.459      | ++(0.931)  | +0.867     | -0.221     |
| CYP-3A4 subst.                  | -0.418      | -0.33       | -0.37      | -0.328     | -0.398     |
| CYP-2C9 inhibitor               | -0.199      | +0.656      | -0.12      | -0.071     | -0.028     |
| CYP-2C9 subst.                  | -0.298      | +0.557      | +0.631     | -0.496     | -0.049     |
| CYP-2C19 inhibitor              | -0.072      | -0.068      | -0.124     | -0.124     | -0.431     |
| CYP-2C19 subst.                 | -0.49       | -0.345      | -0.412     | +0.542     | -0.476     |
| CYP-2D6 inhibitor               | -0.29       | -0.318      | +0.611     | -0.463     | -0.367     |
| CYP-2D6 subst.                  | -0.218      | -0.18       | -0.488     | -0.401     | +0.523     |
| T 1/2 (half-life time)          | 2.138 h     | 0.915 h     | 1.331 h    | 0.745 h    | 0.720 h    |
| Clearance rate (mL/min/kg)      | 0.641       | 1.709       | 1.885      | 1.919      | 1.914      |
| hERG blocker                    | +0.626      | -0.353      | +0.598     | -0.436     | -0.371     |
| (hepatotoxicity (H-HT))         | -0.154      | -0.332      | +0.6       | +0.592     | -0.466     |
| SkinSen                         | -0.235      | -0.278      | -0.264     | -0.278     | -0.329     |
| 50% acute toxicity (LD₅₀ mg/kg) | 419.47      | 648.262     | 858.518    | 737.444    | 860.605    |

TPSA: topological polar surface area; CYP: cytochrome P450; hERG: human ether-a-go-go-related gene.
immune reactions and the surrounding cells [89]. The excessive ROS production results in irreversible oxidative alterations of macromolecules including the carbohydrates, lipids, and proteins [90], thereby leading to increased oxidative stress and triggering the cascade of inflammatory events that activates the transcription of proapoptotic genes and damages hepatocytes [91, 92].

Therefore, the reduced SOD and CAT activities in the liver of STZ-induced diabetic rats may be associated with the free radical generations which in turn decreases the activities of these enzymes. GSH is a cellular defense antioxidant molecule that protects against the progressive destruction of the β cell [93]. The increases in free radicals’ productions in the diabetic rat result in oxidative damage to membrane lipids and proteins and eventually causes a decrease in the levels of GSH, CAT, and SOD as recorded in rats with STZ-induced diabetes. However, our results revealed that treatment with the dietl-eth_T. garckeana attenuated depleted levels of GSH, CAT, and SOD and decreased the LPO. These observations validate the potential of dietl-eth_T. garckeana in preventing free radical generation and maintaining the antioxidant status of diabetic rats [93]. This finding corroborated with literature on oxidative stress-alleviating properties of plant extracts in hyperglycemic rodent [94]. Our findings, therefore, revealed the T. garckeana’s ability to ameliorate oxidative impairment and restore antioxidant status of rats in hyperglycemic condition.

3.8. The dietl-eth_T. garckeana Demonstrated In Vivo Anti-Inflammatory Activities in Xylene-Induced Ear Swelling of Mice.

An in vivo analysis of the anti-inflammatory properties using a xylene-induced ear swelling model in mice revealed that the dietl-eth_T. garckeana significantly (p < 0.001) prevented xylene-induced ear swelling compared to the untreated control. The anti-inflammatory effect demonstrated by the extract was accompanied by a significant (p < 0.001) decrease in WBC counts of treated mice compared to the untreated control (Table 4). Collectively, our
results demonstrated that the dietl-eth_T. garckeana exhibited an anti-inflammatory effect in vivo in addition to its in vitro anti-inflammatory effects.

3.9. HPLC Characterization of the dietl-eth_T. garckeana. To characterized the dietl-eth_T. garckeana we conducted an HPLC analysis (Figure 7) and identified the presence of catechin (6.81e-1 ppm), rutin (8.46 e-1 ppm), myricetin, apigenin (4.019 e-1 ppm), and luteolin (15.09 ppm) with respective retention times (RTs) of 13.64, 24.269, 27.781, 29.58, and 32.23 min. HPLC chromatograms and chemical structures of the compounds are displayed in Figure 7. Luteolin appeared to be the most abundant compound in the dietl-eth_T. garckeana, and thus, we evaluated its prospective for targeting glucose metabolizing enzymes and an inflammatory mediator.

3.10. Drug-ADMET and Likeness Modeling of Compounds Identified from the dietl-eth_T. garckeana. The goal of modern drug discovery and development is to identify a drug candidate with desirable properties within the shortest possible period of time and to avoid time- and cost-consuming approaches which in most cases produces disappointing outcome in the clinics [95, 96]. Hence, drug-likeness and PK analysis is considered an important aspect of the modern drug discovery and development. Our modeling analysis of the drug-PK, and drug-likeness revealed that apigenin, myricetin, luteolin, and catechin identified from the dietl-eth_T. garckeana (Figures 8(a) and 8(b)) were potential drug-like molecules. These compounds passed the drug absorbability test and have desirable bioavailability attribute. P-glycoproteins (P-gp) are responsible for propelling compounds and drugs out of the cells [97]. The identified compounds from the dietl-eth_T. garckeana are nonsubstrate or inhibitors of Pgp, thus suggesting their stability and optimal drug delivery [98]. This was also evident by their absorption and permeability record. The high volume of distribution and low binding of plasma protein by the drug further ascertain the good bioavailability and hinted at the potential good therapeutic index of the compounds but were non-BBB permeant (except for catechin) (Figure 8(b), Table 5). Cytochrome P450 (CYP450) is a

---

**Figure 10:** Docking of luteolin with α-glucosidase. (a) 2-Dimensional depiction of the luteolin complex with α-glucosidase, (b) 3-dimensional image of the hydrophobic links in the complex, and (c) surface representation of luteolin fitted within the binding cavity of the target.
heme containing enzyme family that play central metabolic role on exogenous and endogenous substances [99]. Hence, impeding the activities of these enzyme isoforms may lead to deficient drug metabolism and toxic drug accumulation. Providentially, our data indicated that among the 5 isoforms analyzed, the compounds were nonsubstrate and had inhibitor tendencies for cytochrome P450 1A2 (CYP1A2) and CYP3A4. However, they were nonsubstrate nor inhibitors of CYP2C9, CYP2D6, and CYP2C19. Notwithstanding, luteolin demonstrated its ability to be a substrate for P450 CYP3A4 and CYP1A2, while catechin demonstrated its ability to be a substrate for CYP2D6 (Table 5). The presence of these isoforms in the liver and intestines indicates that these organs are sites of clearance of the compounds. Among the five compounds, luteolin and catechin demonstrated the best and most similar half-lives of 0.745 and 0.720 h, high clearance rates of 1.919 and 1.914 mL/min/kg, and a high safety profile with LD$_{50}$ values of 737.444 and 860.605 mg/kg, respectively. Interestingly, luteolin and catechin demonstrated nontoxic attributes; nonhuman ether go-go-related gene (hERG) blockers, nonhepatotoxic, and were nonirritants in SkinSen assays. Collectively, our analysis revealed that among the five compounds identified, luteolin and catechin exhibited the best drug-PK and drug-likeness characteristic and, thus, were used for receptor-ligand simulation analysis.

3.11. Receptor-Ligand Simulation Analysis Revealed Luteolin’s Properties for Targeting Glucose-Metabolizing Enzymes and an Inflammatory Mediator. Molecular docking is an innovative and widely approved strategies for mimicking a small-molecule interaction with a target receptor/protein [57, 100, 101]. It provides qualitative and quantitative estimation of the affinity between a compound and the corresponding protein/receptor [102]. It also gives a preamble insight into mechanistic aspect of the compound and its

---

![Diagram](image-url)
behavior when in contact with the corresponding target [103–107]. Docking analysis in the present study revealed that luteolin docked efficiently to the substrate interaction domain of α-amylase with a binding affinity of ~8.6 kcal/mol. The complex was bound by four hydrogen bonds to Gln63 (2.62 Å), Asp300 (2.81 Å), Arg195 (2.16 Å), and Glu233 (2.32 Å); pi-pi stacked (Trp59), pi-anion (Asp300), and several van der Waals forces including His305, Leu162, Asp197, His299, Tyr62, Trp58, Ala198, Thr163, and Leu165 (Figure 9). In addition, the complex was bound by four hydrophobic contacts with Thr62A and TRP59A with interaction distances of 3.80, 3.52, 3.75, and 3.64 Å.

Luteolin interacted with glucoamylase by ~8.5 kcal/mol binding efficacy. Luteolin was interposed to the cavity of glucosidase mainly by hydrogen bonds with Ser150 and TRP143 residues of glucosidase domain in respective proximity of 3.28 and 2.52 Å. The luteolin-glucosidase complex stabilization was also achieved by a pi-anion interaction with Asp136, two alkyl bonding with Pro139A and Pro139B, and several van der Waals forces, including Lys134A, Asp215, Lys134B, Asn141, Asn142A, Thr138, Asn142B, Ala151, Leu144, Ser150, and Trp152, molded at the luteolin backbone. In addition, there were three hydrophobic contacts with Thr138A (3.75 Å), Asn142A (3.75 Å), and Lys134B (3.80 Å), and the carboxylate group of luteolin formed a salt bridge interaction with the binding domain of alphaglucoisidase (Figure 10).

The luteolin-cyclooxygenase complex was stabilized by several pi interactions, including pi-alkyl (Val295), pi-sigma (Leu391), amide-pi-stacked (Ala202), and pi-pi T shape (His388), yielding a high ligand-binding affinity of ~8.8 kcal/mol. In total, 13 van der Waals forces with Val444, Phe404, Phe395, Phe407, Phe200, Gln203, His207, His386, Phe210, Tyr385, Leu390, Trp387, and Thr206 residues of the cyclooxygenases were found around the luteolin backbone. In addition, hydrophobic contact of Gln203A with proximity of 3.80 Å was found in the complex (Figure 11). Overall, data presented in this study provides some scientific affirmation based on preclinical model of the anti-inflammatory, hypoglycemic, and antioxidant properties of the T. garckeana extract. This hinted at its potentiality for exploration in the development of alternative therapies for the management and possibly treatment of diabetes complication.

4. Conclusions

The present study provides experimental evidence of the therapeutic efficacy of the diethyl-ether fraction of Thepesia garckeana for treating diabetes. The extract not only enhanced the activities of antioxidant enzymes but also inhibited inflammatory responses, and demonstrated in vivo antidiabetic effects in experimental models. The compound most abundant (luteolin) in the fraction demonstrated good drug-PK and drug-likeness and prospective for the targeting of glucose-catabolizing enzymes. Thus, the present study provides preclinical insights into the bioactive constituents of T. garckeana, its anti-inflammatory and antioxidant effects, and its potential for treating diabetes.

Data Availability

All data used in this study will be made available upon reasonable request.

Conflicts of Interest

The authors declare no conflict of interest.

Authors’ Contributions

All authors read and approved the final version of the manuscript. Uchenna Blessing Alozieuwa and Bashir Lawal contributed equally to this work.

Acknowledgments

ATHW is funded by the Ministry of Science and Technology, Taiwan (111-2314-B-038 -142 and 111-2314-B-038 -098). The authors would like to extend their sincere appreciation to the Taif University Researchers Supporting Project number (TURSP-2020/202) Taif University, Taif, Saudi Arabia.

References

[1] R. A. DeFronzo, “Pathogenesis of type 2 diabetes mellitus,” Medical clinics, vol. 88, no. 4, pp. 787–835, ix, 2004.
[2] L. M. Janssen, M. Hiligsmann, A. M. Elissen et al., “Burden of disease of type 2 diabetes mellitus: cost of illness and quality of life estimated using the Maastricht Study,” Diabetic Medicine, vol. 2020, p. 37, 2020.
[3] R. A. DeFronzo, E. Ferrannini, L. Groop et al., “Type 2 diabetes mellitus,” Nature reviews Disease primers, vol. 1, pp. 1–22, 2015.
[4] A. Maritim, R. A. Sanders, and J. B. Watkins, “Diabetes, oxidative stress, and antioxidants: a review,” Journal of Biochemical and Molecular Toxicology, vol. 17, no. 1, pp. 24–38, 2003.
[5] S. Tsalamandris, A. S. Antonopoulos, E. Oikonomou et al., “The role of inflammation in diabetes: current concepts and future perspectives,” European cardiology review, vol. 14, no. 1, pp. 50–59, 2019.
[6] Y. Wang, J. Zhai, D. Yang et al., “Antioxidant, anti-inflammatory, and antidiabetic activities of bioactive compounds from the fruits of Livistona chinensis based on network pharmacology prediction,” Oxidative Medicine and Cellular Longevity, vol. 2021, 2021.
[7] M. Piero, G. Nzaro, and N. Njagi, “Diabetes mellitus–a devastating metabolic disorder,” Asian journal of biomedical and pharmaceutical sciences, vol. 4, no. 40, pp. 1–7, 2015.
[8] H. Sun, P. Saeedi, S. Karuranga et al., “IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045,” Diabetes Research and Clinical Practice, vol. 183, p. 109119, 2022.
[9] N. Cho, J. Shaw, S. Karuranga et al., “IDF Diabetes Atlas global estimates of diabetes prevalence for 2017 and projections for 2045,” Diabetes Research and Clinical Practice, vol. 138, pp. 271–281, 2018.
[10] O. A. Ojo, M. A. Okesola, L. I. Ekakitie et al., “Gongronema latifoliumBenth. leaf extract attenuates diabetes-induced neuropathy via inhibition of cognitive, oxidative stress and inflammatory response,” Journal of the Science of Food and Agriculture, vol. 100, no. 12, pp. 4504–4511, 2020.
White (NZW) rabbit bucks,” *Comparative Clinical Pathology*, vol. 31, no. 3, pp. 453–463, 2022.

[72] A. O. Owoade, A. Adetutu, O. S. Olorunnisola, and K. S. Ayinde, “The in-vitro antioxidant properties and phytochemical constituents of Citrullus colocynthis methanolic extract,” *Elixir Appl. Botany*, vol. 121, pp. 51556–51562, 2018.

[73] R. Tundis, M. Loizzo, and F. Menichini, “Natural products as α-amylase and α-glucosidase inhibitors and their hypoglycaemic potential in the treatment of diabetes: an update,” *Mini Reviews in Medicinal Chemistry*, vol. 10, no. 4, pp. 315–331, 2010.

[74] W. A. S. Chamaika, T. C. Ho, V. C. Roy et al., “In vitro characterization of bioactive compounds extracted from sea urchin (*Stomatopneustes variolaris*) using green and conventional techniques,” *Food Chemistry*, vol. 361, p. 120866, 2021.

[75] N. Mahmood, “A review of α-amylase inhibitors on weight loss and glycemic control in pathological state such as obesity and diabetes,” *Comparative Clinical Pathology*, vol. 25, no. 6, pp. 1253–1264, 2016.

[76] F. Rolland, J. Winderickx, and J. M. Thevelein, “Glucose-sensing and -signalling mechanisms in yeast,” *FEMS Yeast Research*, vol. 2, no. 2, pp. 183–201, 2002.

[77] K. Ninomiya, Y. Yamaguchi, F. Shinmachi, H. Kumagai, and H. Kumagai, “Suppression of postprandial blood glucose elevation by backwheat (*Fagopyrum esculentum*) alumnum hydrolysate and identification of the peptide responsible to the function,” *Food Science and Human Wellness*, vol. 11, no. 4, pp. 992–998, 2022.

[78] S. Chen, B. Lin, J. Gu et al., “Binding interaction of betulinic acid to α-glucosidase and its alleviation on postprandial hyperglycemia,” *Molecules*, vol. 27, no. 8, p. 2517, 2022.

[79] B.-E. Van Wyk and M. Wink, *Medicinal Plants of the World*, CAB International, 2017.

[80] K. Neha, M. R. Haider, A. Pathak, and M. S. Yar, “Medicinal prospects of antioxidants: a review,” *European Journal of Medicinal Chemistry*, vol. 178, pp. 687–704, 2019.

[81] D. Rajendiran, S. Packirisamy, and K. Gunasekaran, “A review on role of antioxidants in diabetes,” *Asian Journal of Pharmaceutical and Clinical Research*, vol. 11, no. 2, pp. 48–53, 2018.

[82] D. M. Adams and M. T. Yakubu, “Aqueous extract of *Digitaria exilis* germ ameliorate diabetes in streptozotocin-induced diabetic male Wistar rats,” *Journal of Ethnopharmacology*, vol. 249, p. 112383, 2020.

[83] M. C. Petersen, D. F. Vatner, and G. I. Shulman, “Regulation of hepatic glucose metabolism in health and disease,” *Nature Reviews Endocrinology*, vol. 13, no. 10, pp. 572–587, 2017.

[84] B. Lawal, O. K. Shittu, P. C. Osai, A. N. Abubakar, and A. M. Ibrahim, “Evaluation of antioxidant activity of giant African snail (*Achatina magna*) haemolymph in OCH-induced hepatotoxicity in albino rats,” *Journal of Pharmaceutical Research International*, vol. 6, no. 3, pp. 141–154, 2015.

[85] O. I. Abruoma, “Free radicals, oxidative stress, and antioxidants in human health and disease,” *Journal of the American Oil Chemists’ Society*, vol. 75, no. 2, pp. 199–212, 1998.

[86] L. Tappy, “Metabolism of sugars: a window to the regulation of glucose and lipid homeostasis by splanchnic organs,” *Clinical Nutrition*, vol. 40, no. 4, pp. 1691–1698, 2021.

[87] J. Mohamed, A. H. Nazratun Nafizah, A. H. Zariyantey, and S. B. Budin, “Mechanisms of diabetes-induced liver damage: the role of oxidative stress and inflammation,” *Sultan Qaboos University medical journal*, vol. 16, pp. e132–e141, 2016.

[88] M. J. Hossen, M. A. Matin, M. H. Sidker, M. S. Ahmed, and M. Rahman, “Kupffer cells and liver,” in *Recent Advances in Microbial Diversity*, pp. 361–395, Elsevier, 2022.

[89] H. Maeda, Y. Ishima, J. Saruwatari et al., “Nitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH,” *Journal of Controlled Release*, vol. 341, pp. 457–474, 2022.

[90] J. S. Bhatti, A. Sehrawat, J. Mishra et al., “Oxidative stress in the pathophysiology of type 2 diabetes and related complications: current therapeutics strategies and future perspectives,” *Free Radical Biology and Medicine*, vol. 184, pp. 114–134, 2022.

[91] Y. M. Yang, Y. E. Cho, and S. Hwang, “Crosstalk between oxidative stress and inflammatory liver injury in the pathogenesis of alcoholic liver disease,” *International Journal of Molecular Sciences*, vol. 23, no. 2, p. 774, 2022.

[92] C. Matyas, G. Haskó, L. Liaudet, E. Trojnar, and P. Pacher, “Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications,” *Nature Reviews Cardiology*, vol. 18, no. 2, pp. 117–135, 2021.

[93] M. Kaleem, M. Asif, Q. Ahmed, and B. Bano, “Antidiabetic and antioxidant activity of *Annona squamosa* extract in streptozotocin-induced diabetic rats,” *Singapore Medical Journal*, vol. 47, no. 8, pp. 670–675, 2006.

[94] K. O. Karigidi and C. O. Olaiya, “Antidiabetic activity of corn steep liquor extract of *Carcinulus pilosa* and its solvent fractions in streptozotocin-induced diabetic rats,” *Journal of Traditional and Complementary Medicine*, vol. 10, no. 6, pp. 555–564, 2020.

[95] D. Cao, J. Wang, R. Zhou, Y. Li, H. Yu, and T. Hou, “ADMET evaluation in drug discovery. 11. Pharmacokinetics Knowledge Base (PKKB): a comprehensive database of pharmacokinetic and toxic properties for drugs,” *Journal of Chemical Information and Modeling*, vol. 52, no. 5, pp. 1132–1137, 2012.

[96] I. Kola and J. Landis, “Can the pharmaceutical industry reduce attrition rates?,” *Nature Reviews. Drug Discovery*, vol. 3, no. 8, pp. 711–716, 2004.

[97] M. L. Amin, “P-glycoprotein inhibition for optimal drug delivery,” *Drug target insights*, vol. 7, pp. 27–34, 2013.

[98] J. Robert and C. Jarry, “Multidrug resistance reversal agents,” *Journal of Medicinal Chemistry*, vol. 46, no. 23, pp. 4805–4817, 2003.

[99] K. Shankar and H. M. Mehendale, “Cytochrome P450,” in *Encyclopedia of Toxicology*, P. Weder, Ed., pp. 1125–1127, Academic Press, Oxford, 3rd edition, 2014.

[100] Y.-C. Yeh, B. Lawal, M. Hsiao, T.-H. Huang, C. Y. F. Huang, and C.-Y. F. Huang, “Identification of NSP3 (SH2D3C) as a prognostic biomarker of tumor progression and immune evasion for lung cancer and evaluation of organosulfur compounds from *Allium sativum* L. as therapeutic candidates,” *Biomedicine*, vol. 9, no. 11, p. 1582, 2021.

[101] B. Lawal, Y.-C. Wang, A. T. H. Wu, and H.-S. Huang, “Pro-oncogenic c-met/EGFR, biomarker signatures of the tumor microenvironment are clinical and therapy response prognosticators in colorectal cancer, and therapeutic targets of 3-phenyl-2H-benzo[e][1,3]-oxazine-2,4(3H)-dione derivatives,” *Frontiers in Pharmacology*, vol. 12, 2021.

[102] D. M. I. H. Dissanayake, D. D. B. D. Perera, L. R. Keerthirathna et al., “Antimicrobial activity of *Plumbago indica* and ligand screening of plumbagin against methicillin-resistant *Staphylococcus aureus*,” *Journal of Biomolecular Structure and Dynamics*, vol. 40, no. 7, pp. 3273–3284, 2022.
[103] X.-Y. Meng, H.-X. Zhang, M. Mezei, and M. Cui, "Molecular docking: a powerful approach for structure-based drug discovery," *Current Computer-Aided Drug Design*, vol. 7, no. 2, pp. 146–157, 2011.

[104] D. B. Kitchen, H. Decornez, J. R. Furr, and J. Bajorath, "Docking and scoring in virtual screening for drug discovery: methods and applications," *Nature Reviews Drug Discovery*, vol. 3, no. 11, pp. 935–949, 2004.

[105] J.-H. Chen, A. T. H. Wu, B. Lawal et al., "Identification of cancer hub gene signatures associated with immune-suppressive tumor microenvironment and ovatodiolide as a potential cancer immunotherapeutic agent," *Cancers*, vol. 13, no. 15, p. 3847, 2021.

[106] B. Lawal, Y.-C. Kuo, S.-L. Tang et al., "Transcriptomic-based identification of the immuno-oncogenic signature of cholangiocarcinoma for HLC-018 multi-target therapy exploration," *Cell*, vol. 10, no. 11, p. 2873, 2021.

[107] B. Lawal, Y.-C. Kuo, M. R. Sumitra, A. T. Wu, and H.-S. Huang, "In vivo pharmacokinetic and anticancer studies of HH-N25, a selective inhibitor of topoisomerase I, and hormonal signaling for treating breast cancer," *Journal of Inflammation Research*, vol. 14, pp. 1–13, 2021.